SingleCell Biotechnology

Executive Summary

SingleCell Biotechnology is a private company developing a high-throughput, high-content single-cell phenotyping platform that leverages proprietary 3D spatial confinement to assess key cancer stem cell phenotypes—clonogenicity, migration, and dormancy. These phenotypes are linked to tumor aggression, invasion, and recurrence, making the platform valuable for oncology drug development. By enabling phenotype-to-genotype mapping for solid tumors, the company aims to de-risk and expedite drug discovery through strategic partnerships with pharmaceutical companies. Based in Dallas, Texas, and founded in 2016, SingleCell Biotechnology is positioned at the intersection of single-cell genomics and functional phenotyping, addressing a critical bottleneck in cancer drug development: the inability to predict therapeutic response from genotype alone. The platform's ability to provide functional insights at single-cell resolution could significantly improve the success rate of oncology pipelines, particularly for solid tumors where heterogeneity is a major challenge. To date, the company remains privately funded and has not disclosed total funding or valuation.

Upcoming Catalysts (preview)

• Q3 2026Partnership announcement with a major pharmaceutical company for oncology drug screening70% success
• Q4 2026Publication of validation data in a peer-reviewed journal demonstrating platform utility80% success
• 2027Series A funding round led by life sciences venture capital60% success